The Use of NeuroAiD (MLC601) in Postischemic Stroke Patients

Aim . We aimed to assess the efficacy of MLC601 on functional recovery in patients given MLC601 after an ischemic stroke. Methods . This is a retrospective cohort study comparing poststroke patients given open-label MLC601 ( n = 30; 9 female) for three months and matching patients who did not receive MLC601 from our Stroke Data Bank. Outcome assessed was modified Rankin Scale (mRS) at three months and analyzed according to: (1) achieving a score of 0-2, (2) achieving a score of 0-1, and (3) mean change in scores from baseline. Results . At three months, 21 patients on MLC601 became independent as compared to 17 patients not on MLC601 (OR 1.79; 95% CI 0.62–5.2; P = 0.29). There were twice as many patients ( n = 16) on MLC601 who attained mRS scores similar to their prestroke state than in the non-MLC601 group ( n = 8) (OR 3.14; 95% CI 1.1–9.27; P = 0.038). Mean improvement in mRS from baseline was better in the MLC601 group than in the non-MLC601 group (−1.7 versus −0.9; mean difference −0.73; 95% CI −1.09 to −0.38; P < 0.001). Conclusion . MLC601 improves functional recovery at 3 months postischemic stroke. An ongoing large randomized control trial of MLC601 will help validate these results.